Research article · 2014
Conference abstractPublished 8 Nov 2017
Predicting, avoiding and mitigating risk of failure when developing biotherapeutics
Lonza Biologics, UK
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
This presentation will discuss how in silico and in vitro methodologies are employed to perform a developability and immunogenicity risk assessment in order to highlight potential risks of failure for the development of biotherapeutics. In silico methods can be used to evaluate protein sequence and structure to assess the likelihood of immunogenic responses and potential manufacturability issues including aggregation and PTMs. Ex vivo T and B-Cell responses enable the assessment of overall immunogenicity risks; different approaches are highlighted to further identify processed and presented epitopes.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 18 Oct 2018
Transcriptomic biomarkers based approach for predicting the risk of heart failure development in postinfarction patients with the use of the ddPCR method
Conference abstract · 18 Oct 2018
Transcriptomic biomarkers based approach for predicting the risk of heart failure development in post-infarction patients with the use of the ddPCR method
Article · 17 Nov 2025
Applying Social Information Processing, Sensemaking, and Media Richness Theories to Data-Driven Communication for ICT Project Risk Prediction and Mitigation: The Case of Safaricom Kenya
Research article · 16 Feb 2026
Risk Prediction Models for Autogenous Arteriovenous Fistula Maturation Failure in Patients with End-Stage Renal Disease: A Systematic Review and Meta-Analysis
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- BylineArticles whose byline prints “Yvette Stallwood”
